If you’ve been following the development of oral GLP-1 drugs - and based on the traffic to our oral GLP-1 agonists page, plenty of you have - this week brought some notable new data.
Corxel Pharmaceuticals announced positive top-line results from the US Phase 2 trial of CX11, its oral GLP-1 receptor agonist. The numbers: up to 11.5% weight loss at 36 weeks in obese and overweight adults. The company is now moving straight into Phase 3 trials.
That 11.5% figure is worth paying attention to. Here’s why.
The Current State of Oral GLP-1s
The GLP-1 market is currently dominated by injectable drugs. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both weekly injections. They work well - but a lot of people don’t want to inject themselves, and that’s created enormous demand for an oral alternative.
The only oral GLP-1 currently on the market is oral semaglutide (Rybelsus), which is approved for type 2 diabetes but not for weight management at the doses needed for significant weight loss. At the 14mg dose approved for diabetes, the weight loss effect is modest. The higher doses being studied for obesity (25mg and 50mg) are still in trials.
That’s left a gap in the market that several companies are trying to fill.
Corxel’s CX11 Data
The CX11 Phase 2 trial enrolled obese and overweight adults in the US and tested multiple doses over 36 weeks. The key findings:
- Up to 11.5% weight loss at the highest dose tested at 36 weeks
- Continued weight reduction at a consistent rate with no evidence of the trajectory slowing - suggesting longer treatment could produce more weight loss
- Primary endpoints met across the dose range
Corxel’s chief medical officer described the results as “competitive” - which in the context of the current oral GLP-1 landscape, they are. The 11.5% figure at 36 weeks puts CX11 in roughly the same range as oral semaglutide 50mg data from the OASIS trials, and ahead of some other oral GLP-1 candidates that have reported Phase 2 results.
The company has confirmed it will advance CX11 into Phase 3 pivotal trials, with a global program expected to begin in the coming months.
How It Compares
The oral GLP-1 space is getting crowded. Here’s a quick snapshot of where the main candidates stand:
Oral semaglutide (Novo Nordisk) - The 50mg dose showed approximately 15% weight loss in the OASIS 1 trial at 68 weeks. Still awaiting full regulatory approval for the obesity indication. The most advanced oral GLP-1 candidate.
Elecoglipron (AstraZeneca) - Announced a move into Phase 3 development following positive Phase 2 data published in The Lancet. Different mechanism from semaglutide - it’s a small molecule GLP-1 agonist rather than a peptide-based drug.
CX11 (Corxel) - The 11.5% at 36 weeks data. Phase 3 starting soon. The shorter trial duration makes direct comparisons tricky - if the weight loss trajectory continues, 48 or 52-week numbers could be higher.
Orforglipron (Eli Lilly) - Lilly’s oral GLP-1 candidate. Phase 3 data expected later in 2026. Lilly has the advantage of existing infrastructure from Mounjaro/Zepbound manufacturing.
The competition is real, and it’s good news for anyone hoping for more options.
What the Research Says
The challenge with oral GLP-1 drugs has always been bioavailability. Peptides are broken down in the stomach before they can be absorbed. That’s why injectable versions work better - they bypass the digestive system entirely.
The solutions fall into two categories:
Peptide-based oral formulations (semaglutide, CX11) - these use absorption enhancers or other formulation tricks to protect the peptide long enough for it to be absorbed through the stomach lining. Oral semaglutide uses SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) as an absorption enhancer.
Small molecule GLP-1 agonists (elecoglipron, orforglipron) - these are non-peptide drugs that can survive the digestive system naturally. They’re structurally different from the peptide-based drugs but activate the same GLP-1 receptor.
Both approaches have trade-offs. Peptide-based oral drugs typically have lower bioavailability and may need to be taken on an empty stomach. Small molecule drugs are easier to manufacture and may have better oral absorption, but they’re earlier in development.
The CX11 data suggests that the peptide-based approach can produce clinically meaningful weight loss, even if the absolute numbers don’t quite match the injectable versions yet.
Why This Matters for Australia
Oral GLP-1 drugs could significantly change the landscape for Australians interested in metabolic research compounds.
The barriers to injectable medications are real. Some people have needle phobia. Others find weekly injections inconvenient. And in a research context, injectable compounds are harder to study and more expensive to produce.
An effective oral GLP-1 would expand the population that could potentially benefit from this class of compounds. It would also likely be easier to manufacture and distribute, which could affect pricing and availability.
None of these oral candidates are approved in Australia yet. Oral semaglutide (Rybelsus) is TGA-approved for type 2 diabetes, but not at the higher doses being studied for obesity. The other candidates are years from Australian availability.
What to Watch
The oral GLP-1 race is going to produce a lot of data over the next 12-18 months. Key milestones to track:
- Oral semaglutide 50mg approval - Novo Nordisk is expected to file for US approval of the obesity indication. If approved, Australia typically follows 12-18 months later.
- Corxel Phase 3 design - the trial design and endpoints for CX11 Phase 3 will tell us a lot about the company’s confidence in the data.
- Eli Lilly Phase 3 orforglipron data - expected later in 2026. Lilly has deep pockets and existing GLP-1 expertise.
- Elecoglipron Phase 3 progress - AstraZeneca’s small molecule approach is the most differentiated of the candidates.
The bottom line: the oral GLP-1 space is moving fast. Corxel’s CX11 data adds another credible candidate to the mix, and the competition should drive better options for everyone. For the Australian research community, the key message is that the needle-free future is getting closer - but none of these drugs are available here yet, and the timeline is measured in years, not months.
Sources
Source: Corxel Pharmaceuticals - Phase 2 top-line results press release Source: Fierce Biotech - Corxel gears up for global pivotal push Source: The Lancet - Elecoglipron Phase 2 studies (2026) Source: Novo Nordisk - OASIS 1 trial data
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.